AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 20684322
Drug: L-carnitine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-carnitine (2 g/d) and vitamin E
Trial: 18839655
Drug: Topical application
RxNorm normalized name: Talc Topical application Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of human placenta purified extract (PE)
Trial: 18839655
Drug: Topical application
RxNorm normalized name: Talc Topical application Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of povidone iodine (PI)
Trial: 14657817
Drug: 1.25 mg
RxNorm normalized name: menthol 1.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.25 mg levalbuterol
Trial: 14657817
Drug: 2.5 mg
RxNorm normalized name: biotin 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg racemic albuterol
Trial: 8783700
Drug: Oral nonabsorbable
RxNorm normalized name: COLLAGEN HEMOSTAT,ABSORBABLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral nonabsorbable antibiotics for selective bowel decontamination (SBD)
Trial: 8783700
Drug: Conventional prophylaxis
RxNorm normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional prophylaxis with systemic antibiotics (Control)
Trial: 6421196
Drug: High nitrogen
RxNorm normalized name: Isosource High Nitrogen Liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High nitrogen intake (15 mg nitrogen per kcal REE, approximately 21 g/day)
Trial: 6421196
Drug: Low nitrogen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low nitrogen intake (7.5 mg nitrogen per kcal REE, approximately 11 g/day)
Trial: 27861670
Drug: Immediate implant
RxNorm normalized name: IR-3535
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate implant placement (test group)
Trial: 27861670
Drug: Delayed implant
RxNorm normalized name: Drug Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed implant placement (control group)
Trial: 19344527
Drug: High-dose rate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose rate (HDR) brachytherapy
Trial: 17785979
Drug: 1.5 g
RxNorm normalized name: Vaporizer Vicks 1.5 gal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 g chilli powder twice daily along with identical fiber and analgesics
Trial: 17785979
Drug: Analgesics and
RxNorm normalized name: Analgesics and anesthetics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Analgesics and fiber supplement alone
Trial: 14628149
Drug: IR laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IR laser treatment
Trial: 8130021
Drug: Intravenous magnesium
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous magnesium sulphate (8 mmol loading dose over 5 minutes plus 65 mmol over 24 hours)
Trial: 31212115
Drug: Insulin-requiring diabetics
RxNorm normalized name: Diabetic Tussin EX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin-requiring diabetics (IRD)
Trial: 31212115
Drug: Non-insulin requiring
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Non-insulin requiring diabetics (NIRD)
Trial: 28971636
Drug: Lornoxicam (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lornoxicam (20 mg)
Trial: 17101314
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate (880 mug, divided twice daily for 3 months)
Trial: 11329400
Drug: Risperidone (2-6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risperidone (2-6 mg/day, mean modal dose=4.8 mg/day)
Trial: 11329400
Drug: Olanzapine (5-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine (5-20 mg/day, mean modal dose=12.4 mg/day)
Trial: 8970936
Drug: Thyroxine (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thyroxine (8 microg per kilogram of birth weight) administered daily for six weeks
Trial: 8970936
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered daily for six weeks
Trial: 8215267
Drug: Cefonicid (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefonicid (2 g every 12 h)
Trial: 2442991
Drug: Nadolol (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nadolol (mean dose 94 mg daily) plus class I antiarrhythmic agents (quinidine or procainamide)
Trial: 2442991
Drug: Class I
RxNorm normalized name: HLA class I antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Class I antiarrhythmic agents alone
Trial: 12171822
Drug: MDI/DED (metered-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MDI/DED (metered-dose inhaler with delivery enhancement device)
Trial: 12171822
Drug: Single bronchodilator
RxNorm normalized name: Bronchodil
DrugBank: Reproterol (DB12846)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single bronchodilator dose by wet nebulization
Trial: 8583366
Drug: Intravenous milrinone
RxNorm normalized name: Milrinone
DrugBank: Milrinone (DB00235)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous milrinone loading dose of 50 micrograms kg‐1 over 10 min followed by maintenance infusion of 0.45 micrograms kg‐1 min‐1 for moderate renal impairment (n = 10)
Trial: 8583366
Drug: Intravenous milrinone
RxNorm normalized name: Milrinone
DrugBank: Milrinone (DB00235)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous milrinone loading dose of 50 micrograms kg‐1 over 10 min followed by maintenance infusion of 0.35 micrograms kg‐1 min‐1 for severe renal impairment (n = 11)
Trial: 8583366
Drug: Intravenous milrinone
RxNorm normalized name: Milrinone
DrugBank: Milrinone (DB00235)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous milrinone (both groups)
Trial: 2111933
Drug: Oral prophylactic
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral prophylactic penicillin
Trial: 7030973
Drug: Pancuronium (0.05
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pancuronium (0.05 and 0.1 mg/kg i.v.)
Trial: 28062124
Drug: Text message
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Text message group (received two messages weekly for four consecutive weeks)
Trial: 25726788
Drug: Adaptol (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adaptol (1000 mg daily for 30 days)
Trial: 25726788
Drug: Noofen (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Noofen (500 mg daily for 30 days)
Trial: 23082447
Drug: Cabergoline 0.5
RxNorm normalized name: cabergoline 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cabergoline 0.5 mg weekly for 3 months
Trial: 19572930
Drug: 1.25 mg/ml
RxNorm normalized name: menthol 1.25 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.25 mg/ml ropivacaine
Trial: 19572930
Drug: 1.25 mg/ml
RxNorm normalized name: menthol 1.25 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.25 mg/ml ropivacaine with 0.2 mcg/kg/h fentanyl
Trial: 19572930
Drug: 1.5 mg/ml
RxNorm normalized name: thymol 1.5 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 mg/ml ropivacaine
Trial: 19572930
Drug: 1.5 mg/ml
RxNorm normalized name: thymol 1.5 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 mg/ml ropivacaine with 0.2 mcg/kg/h fentanyl
Trial: 19572930
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (1.25 mg/ml ropivacaine)
Trial: 8783388
Drug: GnRH agonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH agonist D‐Trp6‐LHRH (Decapeptyl) 3.2 mg for 12 days
Trial: 1902404
Drug: Intravenous heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous heparin therapy (n = 99)
Trial: 1902404
Drug: Aspirin (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (300 mg/day) and dipyridamole (300 mg/day) (n = 103)
Trial: 6353879
Drug: Ketanserin 20
RxNorm normalized name: ketanserin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketanserin 20 mg t.i.d.
Trial: 6353879
Drug: Ketanserin 40
RxNorm normalized name: ketanserin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketanserin 40 mg t.i.d.
Trial: 6353879
Drug: Ketanserin 60
RxNorm normalized name: ketanserin
DrugBank: Ketanserin (DB12465)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketanserin 60 mg t.i.d.
Trial: 6353879
Drug: Conventional drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional drugs (previous treatment)
Trial: 30032443
Drug: Gynophilus® (Lcr
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gynophilus® (Lcr regenerans®) immediate release capsules administered daily for 21 days
Trial: 30032443
Drug: Gynophilus® slow
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gynophilus® slow release muco-adhesive tablets administered every 3, 4, or 5 days for 21 days
Trial: 30032443
Drug: Gynophilus® slow
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gynophilus® slow release muco-adhesive tablets (administered every 3 or 4 days)
Trial: 21948211
Drug: Restricted perioperative
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Restricted perioperative intravenous fluid regimen
Trial: 21948211
Drug: Standard perioperative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard perioperative intravenous fluid regimen
Trial: 19584979
Drug: Ramipril 10
RxNorm normalized name: ramipril 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramipril 10 mg/day for 12 weeks
Trial: 12048365
Drug: Standard HIV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard HIV prevention services including access to free condoms, risk-reduction counseling, and STI therapy
Trial: 10459399
Drug: Full (102-g)
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Full (102-g) 15-amino acid drink
Trial: 10459399
Drug: Quarter-strength (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quarter-strength (25 g) 15-amino acid drink
Trial: 8665996
Drug: Felodipine oral
RxNorm normalized name: felodipine Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Felodipine oral treatment for 8 weeks
Trial: 1970957
Drug: Flunitrazepam (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flunitrazepam (0.25 to 2 mg/70 kg)
Trial: 1970957
Drug: Lormetazepam (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lormetazepam (0.5 to 4 mg/70 kg)
Trial: 1970957
Drug: Midazolam (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam (1.5 to 12 mg/70 kg)
Trial: 1970957
Drug: Diazepam (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam (4 to 32 mg/70 kg)
Trial: 1970957
Drug: Flumazenil (0.1,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flumazenil (0.1, 0.3 and 0.9 mg/70 kg)
Trial: 7004273
Drug: Diazepam (0.05
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam (0.05 mg/kg)
Trial: 7004273
Drug: d-tubocurarine (0.05
FDA approved: no
EMA approved: no
PMDA approved: no
Description: d-tubocurarine (0.05 mg/kg)
Trial: 23864098
Drug: Tamoxifen, 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen, 5 mg/day
Trial: 21382868
Drug: E(dd)→T(dd)→CMF (dose-intensified
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E(dd)→T(dd)→CMF (dose-intensified chemotherapy)
Trial: 21382868
Drug: EC→T (standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EC→T (standard chemotherapy)
Trial: 19995249
Drug: Levobupivacaine 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levobupivacaine 2.5 mg/ml, 15 ml every three hours for 45 hours
Trial: 17853753
Drug: Premarin tablets
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Premarin tablets (control)
Trial: 11486106
Drug: Lupus anticoagulant
RxNorm normalized name: Lupus anticoagulant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lupus anticoagulant
Trial: 11486106
Drug: Anticardiolipin/anti‐beta(2)‐glycoprotein I
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anticardiolipin/anti‐beta(2)‐glycoprotein I antibodies
Trial: 7833657
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose (30 mCi) radioactive iodine
Trial: 7833657
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose (50‐250 mCi) radioactive iodine
Trial: 7833657
Drug: No postoperative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No postoperative treatment with radioactive iodine
Trial: 24294742
Drug: Sildenafil citrate
RxNorm normalized name: Sildenafil Citrate
DrugBank: Sildenafil (DB00203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sildenafil citrate plus Serophene (25 mg vaginally and 100-150 mg orally)
Trial: 21593403
Drug: KP-1461 (400-3200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KP-1461 (400-3200 mg)
Trial: 21593403
Drug: KP-1461 (3200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KP-1461 (3200 mg)
Trial: 21593403
Drug: KP-1461 (1600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KP-1461 (1600 mg)
Trial: 18284406
Drug: Sildenafil 25
RxNorm normalized name: sildenafil 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sildenafil 25 mg/day at night
Trial: 18284406
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no phosphodiesterase-5 inhibitors)
Trial: 15125329
Drug: Combined vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined vaccine (Twinrix: HAV 720 UE/HBV 20 micrograms)
Trial: 15125329
Drug: Separate vaccines
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Separate vaccines (Engerix B 20 micrograms/Havrix 720 UE)
Trial: 15125329
Drug: Combined vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined vaccine (Twinrix)
Trial: 15125329
Drug: Separate vaccines
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Separate vaccines (Engerix B/Havrix)
Trial: 15125329
Drug: Combined vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined vaccine (Twinrix) and Separate vaccines (Engerix B/Havrix)
Trial: 7641922
Drug: Fallopian sperm
RxNorm normalized name: herring sperm DNA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fallopian sperm perfusion with clomiphene citrate (CC)
Trial: 2787664
Drug: Propofol 2.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol 2.8 mg kg‐1
Trial: 59806
Drug: Nursing intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nursing intervention (bi-weekly visits for two months)
Trial: 28414606
Drug: Isotonic saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isotonic saline (0.9% NaCl) solution
Trial: 25595580
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg intravenous azithromycin, administered 15, 30, or 60 minutes before incision, infused over 1 hour
Trial: 25595580
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg intravenous azithromycin
Trial: 23334506
Drug: HEC gel
RxNorm normalized name: ALCOHOL 73 L in 100 L TOPICAL GEL [Grand Valley Reagents HEC Hand Sanitizer Gel]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HEC gel
Trial: 23334506
Drug: No-gel
RxNorm normalized name: ALCOHOL 80 mL in 100 mL TOPICAL LIQUID [Econo-Gel EA Hand Sanitizer]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No-gel
Trial: 11546903
Drug: Continuous intrathecal
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous intrathecal baclofen infusion (up to 12 months)
Trial: 7810826
Drug: 1% niclosamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% niclosamide lotion applied twice a week
Trial: 31829100
Drug: Enriched marine
RxNorm normalized name: marine non-gelling gelatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enriched marine oil supplement
Trial: 23887151
Drug: NMDA receptor
RxNorm normalized name: NMDA receptor antagonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NMDA receptor blocker ketamine during retention sleep
Trial: 23887151
Drug: AMPA receptor
RxNorm normalized name: Toll-like receptor 9
DrugBank: Toll-like receptor 9 (DB15320)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AMPA receptor blocker caroverine during retention sleep
Trial: 23887151
Drug: NMDA receptor
RxNorm normalized name: NMDA receptor antagonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NMDA receptor coagonist D-cycloserine (DCS) during retention sleep
Trial: 14977793
Drug: Midazolam 0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam 0.4 mg kg(‐1)
Trial: 8203789
Drug: Daflon 500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daflon 500 mg (D500)
Trial: 27797279
Drug: Reference brand
RxNorm normalized name: Eagle Brand Medicated Oil
DrugBank: Eucalyptus oil (DB11114)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference brand enteric‐coated capsules
Trial: 27797279
Drug: Test generic
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test generic enteric‐coated tablets
Trial: 23416142
Drug: α‐lipoic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: α‐lipoic acid (LA) supplementation (600 mg/day) for 28 days
Trial: 17934162
Drug: 0.4 mg
RxNorm normalized name: biotin 0.4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4 mg ITM alone
Trial: 17934162
Drug: 10 microg
RxNorm normalized name: Estradiol 10 microgram vaginal tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 microg ITS plus 0.4 mg ITM
Trial: 15105028
Drug: Supplement containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supplement containing whey protein, amino acids, creatine, and carbohydrate
Trial: 11665963
Drug: Minocycline, 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minocycline, 100 mg twice per day
Trial: 11665963
Drug: Hydroxychloroquine, 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxychloroquine, 200 mg twice per day
Trial: 9440749
Drug: IVMTX 1,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IVMTX 1,000 mg/m2 plus IVMP 1,000 mg/m2 (regimen A)
Trial: 9440749
Drug: LDMTX 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LDMTX 30 mg/m2 every 6 hours for six doses with IVMP 1,000 mg/m2 (regimen B)
Trial: 8089345
Drug: Oral midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral midazolam at a dose of 0.5 mg/kg with 25 mg hydroxyzine pamoate suspension as a vehicle
Trial: 8089345
Drug: Nasal midazolam
RxNorm normalized name: midazolam Nasal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal midazolam at a dose of 0.2 mg/kg
Trial: 8089345
Drug: Both oral
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both oral and nasal midazolam
Trial: 2818919
Drug: Propofol 2.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol 2.25 mg kg‐1
Trial: 2818919
Drug: Thiopentone 4.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiopentone 4.8 mg kg‐1
Trial: 2818919
Drug: Propofol 1.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol 1.8 mg kg‐1
Trial: 2818919
Drug: Thiopentone 4.7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiopentone 4.7 mg kg‐1
Trial: 31754133
Drug: β-blockers (atenolol)
RxNorm normalized name: capsaicin
DrugBank: Capsaicin (DB06774)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: β-blockers (atenolol)
Trial: 20447955
Drug: Hyaluronan (sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyaluronan (sodium hyaluronate; Hyalgan) - 5 intra-articular injections weekly for 5 weeks
Trial: 20447955
Drug: Saline (placebo)
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline (placebo) - 5 intra-articular injections weekly for 5 weeks
Trial: 17925486
Drug: anti-dsDNA antibody
RxNorm normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: anti-dsDNA antibody
Trial: 12834513
Drug: Donepezil (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Donepezil (5 mg/d or more)
Trial: 12834513
Drug: Donepezil (effective
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Donepezil (effective dose for at least 9 to 12 months)
Trial: 31403816
Drug: Internet-delivered cognitive-behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-delivered cognitive-behavioral therapy for CSOs
Trial: 30117129
Drug: Eldecalcitol 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eldecalcitol 0.5 μg
Trial: 30117129
Drug: Eldecalcitol (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eldecalcitol (both doses)
Trial: 21120580
Drug: FOLFOX4 (bevacizumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FOLFOX4 (bevacizumab 5 mg/kg every 2 weeks, FOLFOX4 every 2 weeks)
Trial: 21120580
Drug: FFG (bevacizumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FFG (bevacizumab 5 mg/kg every 2 weeks, FFG weekly for 6 weeks of an 8-week cycle)
Trial: 19913311
Drug: Korean red
RxNorm normalized name: Korean ginseng root
DrugBank: Ginseng (DB01404)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Korean red ginseng 1 g
Trial: 19913311
Drug: Placebo (hop
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (hop extract 0.25 g, caramel color 0.05 g, and red ginseng flavor 0.03 g)
Trial: 11937315
Drug: Rubitecan 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rubitecan 1.5 mg/m2 after overnight fasting